International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 362-365 , April 2010

Efficacy of voriconazole in a murine model of invasive paecilomycosis

Received 1 June 2009 ,Accepted 11 November 2009.

References 

  1. Pastor FJ, Guarro J. Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. Clin Microbiol Infect. 2006;12:948–960
  2. Carey J, D’Amico R, Sutton DA, Rinaldi MG. Paecilomyces lilacinus vaginitis in an immuno-competent patient. Emerg Infect Dis. 2003;9:1155–1158
  3. Castro LGM, Salebian A, Sotto MN. Hyalohyphomycosis by Paecilomyces lilacinus in a renal transplant recipient and a review of human Paecilomyces species infections. J Med Vet Mycol. 1990;28:15–26
  4. Itin PH, Frei R, Lautenschlager S, Buechner SA, Surber C, Gratwohl A, et al. Cutaneous manifestations of Paecilomyces lilacinus infection induced by a contaminated skin lotion in patients who are severely immunosuppressed. J Am Acad Dermatol. 1998;39:401–409
  5. Gutierrez-Rodero F, Morganon M, Ortiz de la Tabla V, Mayoll MJ, Martin C. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus in an immunocompetent host successfully treated with itraconazole: case report and review. Eur J Clin Microbiol Infect Dis. 1999;18:814–818
  6. Orth B, Frei R, Itin PH, Rinaldi MG, Speck B, Gratwohl A, et al. Outbreak of invasive mycoses caused by Paecilomyces lilacinus from a contaminated skin lotion. Ann Intern Med. 1996;125:799–806
  7. Minogue MJ, Playfair TJ, Gregory-Roberts JC, Robinson LP. Cure of Paecilomyces endophthalmitis with multiple intravitreal injections of amphotericin B. Case report. Arch Ophthalmol. 1989;107:1281
  8. D’Mellow G, Hirst LW, Whitby M, Nimmo G, Stallard K. Intralenticular infections. Ophthalmology. 1991;98:1376–1378
  9. Hirst LW, Sebban A, Whitby M, Nimmo G, Stallard K. Non-traumatic mycotic keratitis. Eye (Lond). 1992;6:391–395
  10. Domniz Y, Lawless M, Sutton GL, Rogers CM, Meagher LJ. Successful treatment of Paecilomyces lilacinus endophthalmitis after foreign body trauma to the cornea. Cornea. 2001;20:109–111
  11. O'Sullivan MVN, Withby M, Hirst LW, Apel AJG, Ellis D. Outcome of Paecilomyces species ophthalmic infections treated with systemic voriconazole. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 14–17 September 2003, Chicago, IL. Washington, DC: ASM Press; 2003;p. 448;[Abstract M-972]
  12. Anderson KL, Mitra S, Salouti R, Pham TA, Taylor HR. Fungal keratitis caused by Paecilomyces lilacinus associated with a retained intracorneal hair. Cornea. 2004;23:516–521
  13. Okhravi N, Dart JK, Towler HM, Lightman S. Paecilomyces lilacinus endophthalmitis with secondary keratitis. Arch Ophthalmol. 1997;115:1320–1324
  14. Pintor E, Martin M, Garcia P, Gonzalez M. Endophthalmitis due to Paecilomyces lilacinus after non-surgical penetrating trauma [in Spanish]. Enferm Infecc Microbiol Clin. 2001;19:374–378
  15. Hecker MS, Weinberg JM, Bagheri B, Tangoren IA, Rudikoff D, Bottone E, et al. Cutaneous Paecilomyces lilacinus infection: report of two novel cases. J Am Acad Dermatol. 1997;37:270–277
  16. Gottlieb T, Atkins BL. Case report. Successful treatment of cutaneous Paecilomyces lilacinus infection with oral itraconazole in an immune competent host. Mycoses. 2001;44:513–515
  17. Hall VC, Goyal S, Davis MDP, Walsh JS. Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus: report of three cases and review of the literature. Int J Dermatol. 2004;43:648–653
  18. Yuan X, Wilhelmus KR, Matoba AY, Alexandrakis G, Miller D, Huang AJ. Pathogenesis and outcome of Paecilomyces keratitis. Am J Ophtalmol. 2009;147:691–696
  19. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109:45–54
  20. Clark NM. Paecilomyces lilacinus infection in a heart transplant recipient and successful treatment with terbinafine. Clin Infect Dis. 1999;28:1169–1170
  21. Jade KB, Lyons MF, Gnann JW. Paecilomyces lilacinus cellulitis in an immunocompromised patient. Arch Dermatol. 1986;122:1169–1170
  22. Murciano A, Domer J, Cohen I. Paecilomyces lilacinus infection in an immunocompromised patient. J La State Med Soc. 1990;142:35–37
  23. Legeais JM, Blanc V, Basset D, D’Hermies F, Harrabi S, Frau E, et al. Severe keratomycosis. Diagnosis and treatment. J Fr Ophtalmol. 1994;17:568–573[in French]
  24. Scott IU, Flynn HW, Miller D, Speights JW, Snip RC, Brod RD. Exogenous endophthalmitis caused by amphotericin B-resistant Paecilomyces lilacinus: treatment options and visual outcomes. Arch Ophthalmol. 2001;119:916–919
  25. Martin CA, Roberts S, Greenberg RN. Voriconazole treatment of disseminated Paecilomyces infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2002;35:78–81
  26. Aguilar C, Pujol I, Sala J, Guarro J. Antifungal susceptibilities of Paecilomyces species. Antimicrob Agents Chemother. 1998;42:1601–1604
  27. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol. 2001;39:954–958
  28. Espinel-Ingroff A, Chaturvedi V, Fothergill A, Rinaldi MG. Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study. J Clin Microbiol. 2002;40:3776–3781
  29. Rodríguez MM, Pastor FJ, Serena C, Guarro J. Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. J Antimicrob Chemother. 2009;63:361–364
  30. Van Schooneveld T, Freifeld A, Lesiak B, Kalil A, Sutton DA, Iwen PC. Paecilomyces lilacinus infection in a liver transplant patient: case report and review of the literature. Transpl Infect Dis. 2007;10:117–122
  31. de Hoog GS, Guarro J, Gené J, Figueras MJ. Atlas of clinical fungi. 2nd. ed.. Utrecht, The Netherlands/Reus, Spain: Centraalbureau voor Schimmelcultures/Universitat Rovira i Virgili; 2000;
  32. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard. 2nd ed. Document M38-A2. Wayne, PA: NCCLS; 2008.
  33. Sugar AM, Liu X. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob Agents Chemother. 2001;45:601–604
  34. Graybill JR, Najvar LK, Gonzalez GM, Hernández S, Bocanegra R. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother. 2003;51:1373–1376
  35. Rodríguez MM, Calvo E, Serena C, Mariné M, Pastor FJ, Guarro J. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53:2153–2155
  36. Pujol I, Aguilar C, Ortoneda M, Pastor J, Mayayo E, Guarro J. Experimental pathogenicity of three opportunistic Paecilomyces species in a murine model. J Mycol Med. 2002;12:1286–1289
  37. Garbino J, Ondrusova A, Baligvo E, Lew D, Bouchuiguir-Wafa K, Rohner P. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis. 2002;34:701–703

PII: S0924-8579(09)00560-3

doi: 10.1016/j.ijantimicag.2009.11.018

International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 362-365 , April 2010

Article Tools

* Image Usage & Resolution